Shopping Cart
Remove All
Your shopping cart is currently empty
Pimurutamab
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T80612 Copy Product Info
🥰Excellent
Pimurutamab is a humanized monoclonal antibody modified by glycosylation engineering, which specifically targets epidermal growth factor receptor (EGFR/HER1). By binding to the extracellular domain of EGFR, Pimurutamab blocks its binding to ligands such as EGF and TGF-α, and inhibits receptor dimerization and downstream signal transduction. In addition, the optimized glycosylation modification significantly enhanced its antibody-dependent cell-mediated cytotoxicity (ADCC), making it show good potential in the treatment of solid tumors with high EGFR expression.
Cas No. 2251771-76-1
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $1,050 | 4-6 weeks | 4-6 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Pimurutamab is a humanized monoclonal antibody modified by glycosylation engineering, which specifically targets epidermal growth factor receptor (EGFR/HER1). By binding to the extracellular domain of EGFR, Pimurutamab blocks its binding to ligands such as EGF and TGF-α, and inhibits receptor dimerization and downstream signal transduction. In addition, the optimized glycosylation modification significantly enhanced its antibody-dependent cell-mediated cytotoxicity (ADCC), making it show good potential in the treatment of solid tumors with high EGFR expression. |
| In vitro | In macrophage-mediated phagocytosis assays using human cancer cell lines, Pimurutamab (ATG-031) (nanomolar concentrations) blocked the CD24-Siglec-10 interaction and significantly enhanced the engulfment of tumor cells [1]. |
| In vivo | In human tumor xenograft models, systemic administration of Pimurutamab (ATG-031) significantly suppressed tumor growth and demonstrated synergistic effects when combined with PD-L1 inhibitors [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | EGFR |
| Cas No. | 2251771-76-1 |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Pimurutamab chemical structure | Pimurutamab in vivo | Pimurutamab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.